Join
Login
Join
Login
"Where Everyone Has an MBA"
Tel: (612) 246-4616
Home
Financial Analysis
Companies
Industries
Glossary
About
Frequently Asked Questions
User Testimonials
Contact Us
Navigation
Home
Financial Analysis
Companies
Industries
Glossary
About
- Frequently Asked Questions
- User Testimonials
Contact Us
Avidity Biosciences Inc - SIC # 8731 - COMMERCIAL PHY_SICAL AND BIOLOGICAL RESEARCH
Ticker
Exchange
SIC #
Website
Latest Ticker
RNA
Nasdaq
8731
https://www.aviditybiosciences.com/
Select one of the four (4) financial statement analysis reports below to view the ratio analysis report for your selected company:
Latest Headlines for Avidity Biosciences Inc
Avidity Biosciences to Participate in Upcoming Investor Conferences
- Mar 27th, 2024 1:00 pm
Avidity Biosciences Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
- Mar 21st, 2024 8:05 pm
Insider Sell: CFO Michael Maclean Sells 40,000 Shares of Avidity Biosciences Inc (RNA)
- Mar 15th, 2024 11:01 pm
Top 2% Biotech Avidity Tumbles Despite 'Positive' Results In Treating Muscular Dystrophy
- Mar 4th, 2024 9:02 pm
Avidity Biosciences Announces Positive AOC 1001 Long-term Data Showing Reversal of Disease Progression in People Living with Myotonic Dystrophy Type 1 Across Multiple Endpoints; Same Key Endpoints Agreed for Phase 3 HARBOR™ Trial
- Mar 4th, 2024 12:00 pm
Avidity Biosciences Full Year 2023 Earnings: Misses Expectations
- Mar 1st, 2024 11:43 am
Avidity Biosciences Honors Rare Disease Day®
- Feb 29th, 2024 5:00 pm
Avidity Biosciences Announces Oversubscribed $400 Million Private Placement
- Feb 29th, 2024 12:00 pm
Avidity Biosciences, Inc. (RNA) Reports Q4 Loss, Misses Revenue Estimates
- Feb 28th, 2024 10:20 pm
Avidity Biosciences Inc (RNA) Reports Year-End Financials and Clinical Progress
- Feb 28th, 2024 9:40 pm
Avidity Biosciences Reports Fourth Quarter and Year-End 2023 Financial Results and Recent Highlights
- Feb 28th, 2024 9:05 pm
3 Highly Rated Biotech Stocks to Buy for 300% Gains
- Feb 26th, 2024 11:55 am
Avidity Biosciences Receives FDA Rare Pediatric Disease Designation for AOC 1044 for Treatment of Duchenne Muscular Dystrophy in People with Mutations Amenable to Exon 44 Skipping
- Feb 20th, 2024 2:00 pm
Avidity Biosciences to Present New AOC 1001 Long-term Efficacy and Safety Data from MARINA-OLE™ Trial in People Living with Myotonic Dystrophy Type 1 (DM1) at 2024 Muscular Dystrophy Association (MDA) Clinical & Scientific Conference
- Feb 15th, 2024 10:00 pm
Strength Seen in Akoya (AKYA): Can Its 7.4% Jump Turn into More Strength?
- Feb 7th, 2024 9:13 am
Strength Seen in Avidity Biosciences, Inc. (RNA): Can Its 15.0% Jump Turn into More Strength?
- Jan 29th, 2024 1:54 pm
Avidity Biosciences Announces 2024 Corporate Priorities and Catalysts for Next Stage of Growth
- Jan 5th, 2024 1:30 pm
Avidity Biosciences Reports Positive Data Demonstrating AOC 1044 Delivers Unprecedented Concentrations of PMO in Muscle Following a Single Dose in Healthy Volunteers from Phase 1/2 EXPLORE44™ Trial for Duchenne Muscular Dystrophy
- Dec 13th, 2023 1:30 pm
The Zacks Analyst Blog Highlights Avidity, Bristol Myers Squibb, Vertex, Arcturus and BioVie
- Dec 1st, 2023 10:09 am
Biotech Stock Roundup: RNA Up on BMY Deal Expansion, BIVI Down on Setback & More
- Nov 30th, 2023 3:33 pm
Scroll